SERA · Sera Prognostics, Inc. · Executive Compensation

$2.03 -0.02 (-0.98%) At close · Sep 11

Market Cap

$80.08M

39.45M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Zhenya Lindgardt	President and Chief Executive Officer	$607,000	—	$526,718	$493,971	$392,122	$14,000	$2,033,811
John J. Boniface	Chief Scientific Officer	$439,130	—	$197,442	$186,970	$166,650	$14,000	$1,004,192
Paul Kearney	Chief Data Officer	$426,075	—	$197,442	$186,970	$160,204	$14,000	$984,691

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Paul Kearney	Chief Data Officer	$391,340	—	$378,308	—	$63,594	$13,800	$847,042
Zhenya Lindgardt	President and Chief Executive Officer	$447,257	—	—	—	$232,341	$13,800	$693,398
John J. Boniface	Chief Scientific Officer	$358,904	—	—	—	$58,578	$13,800	$431,282

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Zhenya Lindgardt	President and Chief Executive Officer	$302,954	—	$1,813,500	—	$57,191	$22,638	$2,196,283
Gregory Critchfield	M.D., M.S.	$313,023	—	$231,384	$243,017	$131,400	$594,025	$1,512,849
Austin Aerts	Chief Financial Officer	$307,627	—	$645,178	$23,195	$46,798	$13,200	$1,035,998
John J. Boniface	Chief Scientific Officer	$398,490	—	$316,480	$88,160	$55,633	$13,200	$871,963
Paul Kearney	Chief Data Officer	$407,445	—	$293,300	$63,910	$56,883	$12,414	$833,952

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Gregory Critchfield	M.D., M.S. Chairman, President, and Chief Executive Officer	$584,000	—	—	$989,624	$206,736	—	$1,780,360
Former Chairman	President, and Chief Executive Officer	$584,000	—	—	$989,624	$206,736	—	$1,780,360
Michael R. Foley	Chief Medical Officer	$428,369	—	—	$1,070,870	$134,980	$12,200	$1,646,419
Jay Moyes	Chief Financial Officer Represents the aggregate grant date fair value of option awards granted in the applicable fiscal year. Grant date fair value is calculated in accordance with Accounting Standards Codification (“ASC”) Topic 718 (“ASC 718”) issued by the Financial Accounting Standards Board. For the assumptions relating to valuations of equity awards made to our named executive officers, see Note 11 to our audited financial statements, which are included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the SEC on March 22, 2023. Consists of bonus payments received under our non-equity incentive compensation plans based upon satisfaction of performance goals. See “Executive Compensation — Non-Equity Incentive Compensation Plan.” Consists of matching contributions made under our 401(k) plan on behalf of each NEO. Dr. Foley’s employment commenced on December 30, 2021, and his compensation in 2021 consisted of a sign-on bonus.	$421,100	—	—	$388,250	$126,300	$9,889	$945,539
John J. Boniface	Chief Scientific Officer Represents the aggregate grant date fair value of RSU awards granted in the applicable fiscal year. Grant date fair value is calculated in accordance with Accounting Standards Codification (“ASC”) Topic 718 (“ASC 718”) issued by the Financial Accounting Standards Board (“FASB”). For the assumptions relating to valuations of RSU awards made to our named executive officers, see Note 2 to our audited financial statements, which are included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on March 20, 2024. Represents the aggregate grant date fair value of option awards granted in the applicable fiscal year. Grant date fair value is calculated in accordance with ASC 718 issued by the FASB. For the assumptions relating to valuations of equity awards made to our named executive officers, see Note 10 to our audited financial statements, which are included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on March 20, 2024. Consists of bonus payments received under our non-equity incentive compensation plans based upon satisfaction of performance goals. See “Executive Compensation — Non-Equity Incentive Compensation Plan.” For Ms. Lindgardt, other compensation in 2023 consists of 17,473 of fees paid for her service as a non-employee member of our board of directors prior to her appointment as President and Chief Executive Officer on June 8, 2023 and 5,165 of matching contributions made under our 401(k) plan. In 2022, Ms. Lindgardt’s other compensation consists of fees paid for her service as a non-employee member of our board of directors. For Dr. Critchfield, other compensation in 2023 consists of 584,000 of severance pay in accordance with his Retirement and Transition Agreement and 10,025 of continued health insurance coverage. For Mr. Aerts and Dr. Boniface, other compensation consists of matching contributions made under our 401(k) plan.	$406,100	—	—	$280,787	$127,159	$12,200	$826,246
Austin Aerts	Chief Financial Officer	$230,150	—	—	$91,089	$57,500	$10,709	$389,448
Zhenya Lindgardt	President and Chief Executive Officer	—	—	—	$120,000	—	$37,500	$157,500

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Robert G. Harrison	Chief Information Officer	$238,773	—	—	$1,601,907	$67,804	—	$1,908,484
Benjamin G. Jackson	—	$223,260	—	—	$1,294,287	$100,424	—	$1,617,971
Gregory Critchfield	M.D., M.S. Chairman, President, and Chief Executive Officer	$500,100	—	—	$453,519	$275,000	—	$1,228,619
Jay Moyes	Chief Financial Officer Represents the aggregate grant date fair value of option awards granted in the applicable fiscal year. Grant date fair value is calculated in accordance with Accounting Standards Codification (“ASC”) Topic 718 (“ASC 718”) issued by the Financial Accounting Standards Board. For the assumptions relating to valuations of equity awards made to our named executive officers, see Note 11 to our audited financial statements, which are included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the SEC on March 22, 2023. Consists of bonus payments received under our non-equity incentive compensation plans based upon satisfaction of performance goals. See “Executive Compensation — Non-Equity Incentive Compensation Plan.” Consists of matching contributions made under our 401(k) plan on behalf of each NEO. Dr. Foley’s employment commenced on December 30, 2021, and his compensation in 2021 consisted of a sign-on bonus.	$380,100	—	—	$398,591	$167,200	—	$945,891
Michael R. Foley	Chief Medical Officer	—	—	—	$10,000	—	—	$10,000

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Gregory Critchfield	M.D., M.S. Chairman, President, and Chief Executive Officer	$400,000	—	—	$408,944	$144,000	—	$952,944

Executive changes

Person	Role	Change	Effective	Filed
Austin Aerts	Chief Financial Officer	Terminated	2026-09-08	2026-08-19
Scott Gleason	Chief Financial Officer and Treasurer	Appointed	2026-08-31	2026-08-19
Mark Capone	Class II director	Appointed	2026-07-01	2026-06-30
Jeffrey T. Elliott	member of the Board of Directors	Resigned	2026-06-04	2026-06-01

Key facts CIK 1534969 CUSIP 81749D107 13F (30d) 13 filings 13 filers Visit website Investor relations